Unlike FDA, European regulators refuse to clear chloroquine for COVID-19 without data
April 3, 2020
By Neozene

This article originally appeared in FiercePharma and was written by Eric Sagonowsky Chloroquine and hydroxychloroquine have drawn more attention—and certainly more presidential support—than any other drug during the global quest to find an effective coronavirus therapy. Now, days after the FDA gave them an emergency approval to treat COVID-19, European regulators are limiting their COVID-19 use to clinical trials only. The decision comes as limited data—some of it questionable—rolls in about the drugs and their potential as COVID-19 therapies. A French study that’s made headlines continues to draw fire, but brand-new data from China add

Read More

Vir Biotechnology to Test COVID-19 Antibody ‘In the Summer’
March 27, 2020
By Neozene

This article originally appeared in FierceBiotech and was written by Ben Adams One-quarter of the world is now hunkering down to weather the infectious storm that is COVID-19, and Vir’s insistence on the importance of infectious disease research is prescient to say the least. Today, the biotech, helmed by former Biogen CEO George Scangos, says it has mapped out “multiple antibodies” that can “neutralize” SARS-CoV-2, the virus causing COVID-19. The San Francisco biotech says it will kick-start a phase 1/2 clinical test as early as this summer, in “3 to 5 months.” Vir

Read More

How Neozene is Responding to COVID-19
March 20, 2020
By Neozene

With the ongoing threat of COVID-19 (“Coronavirus”) sweeping the state, country and world, we would like to give you a brief update on how we’re responding to the crisis.   First and foremost, we are still going strong, but the health and safety of our employees and customers remains our top priority—as such, we have sent the majority of our staff home so they can work remotely. The work we do is critical to biomedical and pharmacological research, and we’re committed to working on solutions to ease the burden of

Read More